The drug initially used to treat diabetes has been transformed into “fever” to aid in weight loss
Summary
One Ozempic user suffered severe intestinal damage allegedly caused by the drug. He is now suing the pharmaceutical company responsible for the drug for “failing to adequately flag the risk of gastroparesis on the packaging.”
An Ozempic user will suffer from “diarrhea for the rest of her life” following severe intestinal damage allegedly caused by the drug. According to daily email, The woman, whose identity has not been revealed, is one of at least 12 victims who have taken legal action against Novo Nordisk, the pharmaceutical company that created the commonly used weight-loss drugs Ozempic and Wegovy.
The main accusation is that use of the drug caused gastroparesis, a rare disease that affects the spontaneous movement of the stomach muscles, causing nausea, vomiting, pain and difficulty digestion.
According to the newspaper, the woman was diagnosed with a “life-threatening intestinal injury” and the probable cause, according to the doctors who treated her, was Ozempic.
The victim also underwent an eight-hour surgery to try to repair his colon. Although she managed to survive, surgeons said she would suffer “for the rest of her life” and would “never have a large bowel movement again.” “Her life was forever changed by the use of Ozempic,” an excerpt from the lawsuit says.
The woman now accuses Novo Nordisk of “not having adequately reported the risk of gastroparesis on the drug packaging”. It is unclear whether she was using the drug to lose weight or to treat diabetes. It is also not known how long she had been taking medications before the intestinal injury.
Source: Terra

Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.